tert-butyl 4-(chloro(methylsulfonyloxyimino)methyl)piperidine-1-carboxylate | 945989-36-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-(chloro(methylsulfonyloxyimino)methyl)piperidine-1-carboxylate
• 英文别名: Tert-butyl 4-(chloro(methylsulfonyloxyimino)methyl)piperidine-1-carboxylate；tert-butyl 4-(C-chloro-N-methylsulfonyloxycarbonimidoyl)piperidine-1-carboxylate
• CAS: 945989-36-6
• 化学式: C₁₂H₂₁ClN₂O₅S
• 分子量: 340.828
• InChiKey: QZEXDYYNSSEBFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  93.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(chloro(methylsulfonyloxyimino)methyl)piperidine-1-carboxylate 在 吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 反应 2.0h， 生成 2-hydroxy-1-(4-(5-(3-phenoxy-5-(pyridin-2-ylthio)pyridin-2-ylamino)-1,2,4-thiadiazol-3-yl)piperidin-1-yl)ethanone
  参考文献：
  名称：

  Discovery and preclinical development of AR453588 as an anti-diabetic glucokinase activator

  摘要：

  Glucose flux through glucokinase (GK) controls insulin release from the pancreas in response to high levels of glucose. Flux through GK is also responsible for reducing hepatic glucose output. Since many individuals with type 2 diabetes appear to have an inadequacy or defect in one or both of these processes, identifying compounds that can activate GK could provide a therapeutic benefit. Herein we report the further structure activity studies of a novel series of glucokinase activators (GKA). These studies led to the identification of pyridine 7 2 as a potent GKA that lowered post-prandial glucose in normal C57BL/6J mice, and after 14d dosing in ob/ob mice.

  DOI：

  10.1016/j.bmc.2019.115232
• 作为产物：
  描述：

  1-叔丁氧羰基哌啶-4-甲醛 在 N-氯代丁二酰亚胺 、 盐酸羟胺 、 sodium carbonate 、 三乙胺 作用下， 以 甲醇 、 乙醚 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.18h， 生成 tert-butyl 4-(chloro(methylsulfonyloxyimino)methyl)piperidine-1-carboxylate
  参考文献：
  名称：

  WO2008/118718

  摘要：

  公开号：

文献信息

• 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS
  申请人：Aicher Thomas Daniel

  公开号：US20100099713A1

  公开（公告）日：2010-04-22

  Provided are compounds having the Formula I or salts thereof, wherein R 2 , L, R 3 , R 11 , D 2 and R 13 are as defined herein, that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供的化合物具有I式或其盐，其中R2、L、R3、R11、D2和R13的定义如本文所述，可用于治疗和/或预防由葡萄糖激酶活性不足引起的疾病，如糖尿病。还提供了治疗或预防由葡萄糖激酶活性不足或可以通过激活葡萄糖激酶治疗的疾病和疾病的方法。
• 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS
  申请人：Aicher Thomas Daniel

  公开号：US20100105659A1

  公开（公告）日：2010-04-29

  Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供了一些化合物，这些化合物在治疗和/或预防由葡萄糖激酶活性不足引起的疾病中非常有用，例如糖尿病。同时提供了治疗或预防由葡萄糖激酶活性不足或可以通过激活葡萄糖激酶治疗的疾病和疾病的方法。
• 2-aminopyridine analogs as glucokinase activators
  申请人：Aicher Thomas Daniel

  公开号：US08362037B2

  公开（公告）日：2013-01-29

  Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供了一些化合物，这些化合物在治疗和/或预防由葡萄糖激酶活性不足引起的疾病（如糖尿病）方面非常有用。同时还提供了治疗或预防由葡萄糖激酶活性不足或可以通过激活葡萄糖激酶来治疗的疾病和疾病的方法。
• 2-aminopyridine derivatives as glucokinase activators
  申请人：Aicher Thomas Daniel

  公开号：US08431713B2

  公开（公告）日：2013-04-30

  Provided are compounds having the Formula I or salts thereof, wherein R2, L, R3, R11, D2 and R13 are as defined herein, that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供了具有公式I或其盐的化合物，其中R2、L、R3、R11、D2和R13的定义如本文所述，这些化合物在治疗和/或预防由葡萄糖激酶活性不足介导的疾病，如糖尿病等方面是有用的。还提供了治疗或预防由葡萄糖激酶活性不足或可以通过激活葡萄糖激酶治疗的疾病和疾病的方法。
• WO2007/89512
  申请人：——

  公开号：——

  公开（公告）日：——